Upcoming Events at the San Diego Chapter

Chapter Homepage

"Deal Trends & New Developments in Oncology: Setting the Pace for the Biotechnology Industry"

Thursday, February 15, 2007
6:00-8:00 p.m.

Sponsored by:

TBA

SPEAKERS:

Opening Remarks:
Linda M. Pullan, Ph.D. , Founder, Pullan Consulting, Newbury Park, CA

Panelists:
David Guy, Chief Commercial Officer, Favrille, San Diego, CA
Kerry Dance, Ph.D., Managing Director - Hamilton Bioventures LP
Facilitator:
Vasu Pestonjamasp, Ph.D., Managing Director, Bio-I.P. Management Co., San Diego, CA

PROGRAM DESCRIPTION:
In 1971 President Nixon signed the National Cancer Act declaring the "War on Cancer" and setting the stage for America's "Healthcare Vietnam", a war of attrition that still regularly claims more victims from among friends & family.

And like Defense Dept. cost overruns, deal terms in the oncology space have consistently set the bar for new highs in the biotech & pharmaceutical industries.

GlaxoSmithKline's agreement in December with Genmab A/S of Denmark to license a new treatment for leukemia (HuMax-CD20) set another world record, consisting of $2.1 Billion in total payments and potential milestones. Genmab received an upfront license fee of $102 million, coincident with GSK investing $357 million to buy 10.1 % of Genmab's outstanding stock. Downstream milestones could total $ 1.6 Billion should the Phase III drug reach the marketplace.

Moreover, the oncology field is often the source of innovative deal terms and licensing agreements, starting way back in 1995 when San Diego's own early-stage company, IDEC, negotiated a revenue-sharing and co-marketing agreement for the drug Rituxan with the much-larger Genentech.

The deal terms also have a bearing on clinical trials for drugs, and sponsorships decisions, as the costs associated with the trials can be enormous. 

No matter what your area of focus in the healthcare industry, deal trends and business models in oncology may instruct and inform your own licensing, business development, I.P., and clinical trials strategies. Please join us for a deal-trend update and panel discussion on the largest and most seminal field of biotechnology and healthcare.

To learn more, please join us on Thursday, February 15 at the Licensing Executives Society (LES) Meeting at La Jolla Marriott.

DATE:
Thursday, February 15, 2007

TIME:
6:00 p.m. – 6:50 Registration, Networking, Cocktails and Appetizers
6:50 p.m. – 7:00 p.m. Chapter Business
7:00 p.m. – 8:00 p.m. Panel Discussion

LOCATION:
Marriott San Diego La Jolla, 4240 La Jolla Village Drive

COST:
Pre-Register by 12 noon on Wednesday, February 14, 2007

$35 Members by Wednesday, February 14, $45 at the door (cash or check only)
$40 Non-Members by Wednesday, February 14, $50 at the door (cash or check only)

$20 Member Student Rate by Wednesday, February 14, $20 at the door (cash or check only)
$25 Non-Member Student Rate by Wednesday, February 14, $25 at the door (cash or check only)

REGISTRATION OPTIONS:
You have the option of registering online and paying either by credit card OR check

Pre-registration not only guarantees you a seat, but it also saves you $10.

LES Members, click here to register online with your credit card;

Non-Members, click here to register with your credit card;

LES Student Members, click here to register with your credit card;

Non-Member Students, click here to register with your credit card;

Seating is limited and will be on a first come, first served basis. Please note that we will still need to receive your reservation by Wednesday, February 14, to guarantee your registration. The address to mail your check to is:

Chris Steinhardt
c/o Knobbe Martens Olson & Bear LLP
550 West C Street, Suite 1200
San Diego, CA 92101
619-235-8550 619-235-0176 Fax
e-mail: csteinhardt@kmob.com

For additional information, please contact:

NOTE:   This presentation will qualify for MCLE credit

PANELISTS’ BIOGRAPHIES

Linda M. Pullan, Ph.D. -- FOUNDER, Pullan Consulting 
Linda M. Pullan, Ph.D. is the founder of Pullan Consulting (lpullan@msn.com ; 805-558-0361), offering biotech business development consulting.  Linda was previously VP of Business Development at Kosan Biosciences.  Prior to joining Kosan, Linda was the Director of Licensing at Amgen where she created and led licensing team for oncology and hematology.  Linda began her pharmaceutical industry experience as a drug discovery researcher in neuroscience at Monsanto/Searle (now part of Pfizer) and later at AstraZeneca.  At AstraZeneca, she switched to licensing, working on technologies and early drug candidates for all therapeutic areas.  Her Ph.D. is in Biochemistry from the University of California at Riverside, and her BS is in Chemistry from the University of Utah.  She has authored 66 publications.  Her deal sheet lists 8 major deals and more than 10 others.

David Guy -- Chief Commercial Officer, Favrille
David Guy joined Favrille with 18 years of experience in marketing and sales, including more than 10 years specifically dedicated to commercializing oncology products and managing leading brands such as Rituxan®, Herceptin®, Fludara® and Taxotere®. Prior to joining Favrille, Mr. Guy served as Vice President, Global Strategic Marketing and Business Development, Oncology at Schering AG/Berlex. Previously, he served as Director, Oncology Marketing at Genentech, where he was responsible for the marketing activities for both Rituxan and Herceptin. Prior to Genentech, Mr. Guy spent six years at Sanofi-Aventis as U.S. Business Unit Head, Oncology (Sanofi), and held several key commercial positions that contributed to the success of Taxotere (Aventis/RPR). Mr. Guy earned his Bachelor of Science degree in Biology with a specialization in Molecular Genetics from McMaster University in Hamilton, Ontario.

Dr. Kerry Dance, Managing Director - Hamilton Bioventures LP
Dr. Kerry Dance, Managing Director of Hamilton Bioventures LP, has 25 years of executive experience, acting both as a scientist and a leader. He has previously served as CEO of Advanced Distillation Technology, a seawater desalination company, as well as President of the S-Cubed Division of Maxwell Laboratories, Inc., and Vice President of Technology for Aerojet General Corporation.  Dr. Dance came to San Diego in 1978 and became President of General Atomics Corporation. While at General Atomics he founded an in-house venture enterprise, (one of the first in San Diego) which spun off several successful companies.  Dr. Dance attended Stanford University where he received a Ph.D. in Mechanical Engineering with a Nuclear Option and B.S. and M.S. degrees in Engineering Science

Vasu Pestonjamasp, Ph.D. , Managing Director -- Bio-I.P. Management Co.
Dr. Pestonjamasp is the Managing Director of Bio-I.P. Management Co., a San Diego-based consulting firm specializing in scientific, technical, and business-related writing, and advising about business development/marketing strategies in various areas, with a major focus on oncology.  Vasu has been the originator, organizer, and Chair/Co-chair of such first-in-class conferences as Strategic Research Institute’s (SRI’s) Pharma & Biotech Intellectual Property & Patents Summit, as well as annual business workshops and technical sessions held during BIO-Europe and IBC’s BioAsia conferences.  Vasu has received numerous awards for academic excellence, obtained grant funding and has a distinguished record of research published in various peer-reviewed scientific journals. She completed her postdoctoral research at Harvard Medical School and the University of California San Diego (UCSD), and also did project work at the University of Massachusetts Medical Center in Worcester, Massachusetts.

Vasu received her Ph.D. from Cancer Research Institute (affiliated to Tata Memorial Center, Bombay, India, which is a sister institution of M.D. Anderson Cancer Center, Texas, USA).